Navigator’s Q3 Was a Supply Story, Not a Demand Story
With inventories 25% below normal and capex rolling off, the paper maker is set up for a Q4 volume-and-cost recovery — if tissue stops leaking.
NVG.LS · Earnings Call · 2026-10-27
The trough had a lot of moving parts
Navigator’s third quarter was not a demand failure. It was a supply-availability failure. Turnover for the first nine months reached EUR 1,333 million and EBITDA EUR 212 million, but the quarterly pattern was distorted by weather, a cyberattack, seven grid disturbances and extended maintenance at Setúbal, Aveiro and Figueira da Foz. Management’s own framing is blunt:
Weather-related disruptions on Q1 were followed by unplanned shutdowns caused by external factors, including the cyber attack and seven power grid disturbances.
Those external events matter because they hit a system already running with very thin inventories. The resulting production costs were the largest negative swing in the Q2-to-Q3 EBITDA bridge, not price. That distinction is important: the cost pressure was largely temporary and operational, not a structural collapse in pricing.
Price leadership is real; mix is noisy
Navigator again led European uncoated woodfree price increases — three moves by June — while most competitors were still on their first or second. It also pushed through multiple increases overseas and two in the U.S. The payoff shows up in uncoated woodfree prices: the average premium over the PIX A4 Copy-B benchmark rose 6 percentage points versus 2025, and the Navigator Office Paper brand held a 31% premium, near record levels. Management says September prices across pulp, paper and packaging rose 5% to 17% versus the December average. In packaging, the message is even cleaner: “September pricing is up 17% compared to last December's average and 6% quarter-on-quarter.” — João Lé · 2026-10-27 The PM3 conversion is complete, adding 90,000-100,000 tonnes of low-grammage kraft paper capacity and taking total packaging capacity to 350,000-400,000 tonnes. Packaging volumes rose 44% year-on-year to 91,000 tonnes and now represent 6% of group sales. That is a genuine growth engine, not a science project.
Tissue is the weak spot. tissue volumes came in at 160,000 tonnes, with U.K. competition forcing a choice between volume and margin. Navigator chose margin: “we have decided to protect margins and prices rather than participating in a value-destroying spiral on the tissue prices.” — António Redondo · 2026-10-27 That is consistent with last October’s language, when management said it had “decided to net down some sales that we believe are not profitable.” — Jose de Araujo, Director · 2025-10-28 The difference now is that the U.K. transformation program is in its most demanding phase, and the new Aveiro tissue machine is still a 2028 event. Tissue will remain a drag until integration and price recovery arrive.
The inventory buffer is gone — and that cuts both ways
The most actionable line on the call was about stocks. Inventories ended the quarter 25% below the historical average, and management does not plan to rebuild them for at least two quarters. “It is going to be very difficult to further stretch our existing stocks... I don't think it is the moment to rebuild stocks.” — António Redondo · 2026-10-27 This is not new: back in May, management already warned that healthy order books were running around 45 days against a normal 20-25 days, while stocks were unusually low. But the setup has changed. The major maintenance and investment shutdowns are behind them, so Q4 should bring better volumes and lower costs. “We expect better volumes... and lower costs also for the quarter.” — António Redondo · 2026-10-27 If demand holds, operating leverage flows straight to the P&L because there is no inventory cushion to absorb upside. The flip side is equally real: any unplanned outage now has no buffer, and Q4/Q1 are seasonally strong periods for uncoated woodfree demand.
Capex cliff meets decarbonization dividend
The balance-sheet story is shifting. Navigator spent EUR 190-200 million a year from 2022-2026 on decarbonization, packaging and tissue. That peak is over. Management now guides to roughly EUR 100 million a year on average over the next five years, with 2027 and 2028 still above that line because of the Aveiro tissue mill. “We are going to move from EUR 190 million to EUR 200 million to around EUR 100 million.” — António Redondo · 2026-10-27 That is a meaningful historical CapEx reset. It restores free cash flow, lowers net debt at 2.66x EBITDA, and — crucially — gives Navigator the financial room to pursue tissue M&A if a sound target appears.
The decarbonization program is also being reframed. It is no longer just an ESG cost. Six projects worth about EUR 193 million should cut scope 1 and 2 emissions by close to 300,000 tonnes of CO2 and reduce natural gas consumption by roughly 50% versus 2018 by 2027. “By 2027... our natural gas consumption is expected to be closer to 50% below 2018 levels.” — António Redondo · 2026-10-27 Navigator enters 2027 with no natural gas hedging, so it is fully exposed to spot prices — but on a much smaller consumption base. That is the real structural change: lower carbon costs and lower exposure to fossil energy make the industrial cost base less fragile, even if the headline gas price stays volatile. Previous calls emphasized decarbonization targets; this one explicitly sells the resilience dividend. That is a subtle but important shift in the equity story.
One caution: the U.K. tissue timeline has slipped. In May, management said the transformation would be “largely completed by the end of this year, Q1 2027.” — Antonio Redondo, Director · 2026-05-12 Today it is framed as completion by the end of the first half of next year. The company calls it on track, but the buffer has moved by a quarter or two. With tissue already the weakest link, that is worth watching.
The setup is better than the print
The market may read Q3 as another messy operational quarter. The better read is a company exiting a heavy investment and maintenance cycle with prices moving its way, packaging ramping, inventories depleted and capex about to halve. This is not a broad sector wave — Navigator’s current keyword set is company-specific, not a global top-75 theme — but it is a credible self-help and normalization story. The risk is that tissue competition and unhedged 2027 gas prices keep the recovery from feeling clean. For now, the burden of proof is on Q4: better volumes, lower costs and no new external shocks. If that lands, the capex cliff and depleted inventory buffer could turn a supply-constrained year into a surprisingly strong 2027.